Cogent Biosciences, Inc.

NASDAQ:COGT

Biotechnology

Healthcare
$27.81 +2.60%

+$0.88 today

Market cap
$4.84B
Beta
0.35
P/E (TTM)
-6.6
EPS (TTM)
-$5.26
52W Low $6.92High $43.73

Volume 2.71M

Average 2.15M

COGT Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Cogent Biosciences, Inc.NASDAQ: COGT

Research & Development · Q2 FY2026 · quarter ended Jun 2026

Research & development grows in line with its trailing trend

Q2 FY2026 research & development of $70.81M rose 16.0% year over year, in line with the +15.9% change in trailing-twelve-month research & development. Sequentially, it fell 6.0% from the prior quarter. Over 3 fiscal years it compounded at +30.4% a year.

Context

  • Research & development increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +16.0% holds above the trailing-twelve-month pace of +15.9%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$70.81M-6.0% QoQ
Last fiscal yearDec 2025
$269.78M+16.0% YoY
LTMJun 2026
$289.55M+15.9% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+16.0%——
1 year+16.0%——
3-year CAGR+30.4%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
269.78M USD
Year-over-year change
+16.0%
4-year CAGR
+48.2%

Research & Development vs competitors

How COGT compares with its peers on the latest reported figures

  • COGT's LTM Jun 2026 research & development of $289.55M is the 5th highest of the 10 companies compared; the peer median is $260.36M.
  • Its year-over-year change of +15.9% is the 3rd highest of 10, against a peer median of +9.1%.
  • Over three fiscal years its annual growth of +30.4% compares with a peer median of +22.0%.
COGT Competitors Peer median
Research & Development for COGT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
INCYIncyte CorporationLTM Jun 2026$2.15B +9.1%+8.9%37.0%
RCUSArcus Biosciences, Inc.LTM Jun 2026$497M +2.5%+22.0%424.8%
IDYAIDEAYA Biosciences, Inc.LTM Mar 2026$339.54M +5.2%+52.0%150.7%
NRIXNurix Therapeutics, Inc.LTM Aug 2026$331.95M +10.2%+18.6%47.3%
COGTCogent Biosciences, Inc.LTM Jun 2026$289.55M +15.9%+30.4%—
KURAKura Oncology, Inc.LTM Mar 2026$260.36M +37.3%+39.3%363.4%
SNDXSyndax Pharmaceuticals, Inc.LTM Mar 2026$255.99M +3.7%+29.7%117.9%
TNGXTango Therapeutics, Inc.LTM Sep 2026$152.48M +14.3%+7.7%—
AVBPArriVent BioPharma, Inc. Common StockLTM Mar 2026$129.68M +5.2%+71.4%—
MAZEMaze Therapeutics, Inc.LTM Mar 2026$114.57M +28.4%+7.1%572.9%
Peer median (excluding COGT) $260.36M+9.1%+22.0%150.7%

Competitors are the stored peer set for COGT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00004.62M
Gross Profit0000(4.62M)
Gross Margin—————
Research & Development55.91M121.63M173.76M232.66M269.78M
Selling, General & Admin19.64M26.21M34.38M43.28M63.58M
Operating Expenses75.55M147.84M208.13M275.94M328.74M
Depreciation & Amortization147K5.88M3.59M4.35M4.58M
EBITDA(72.13M)(130.37M)(188.82M)(251.51M)(321.29M)
EBITDA Margin—————
Operating Income(75.55M)(147.84M)(208.13M)(275.94M)(333.36M)
Operating Margin—————
Interest Income467K3.99M13.08M18.09M14.69M
Interest Expense03.99M003.06M
Other Income / Expenses3.28M7.6M15.72M20.08M4.43M
Income Before Tax(72.27M)(140.24M)(192.41M)(255.86M)(328.94M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(72.27M)(140.24M)(192.41M)(255.86M)(328.94M)
Net Margin—————
EPS (Basic)(1.85)(2.26)(2.42)(2.32)(2.04)
EPS (Diluted)(1.85)(2.26)(2.42)(2.32)(2.04)
Weighted Avg Shares38.73M58.74M79.66M110.46M160.98M
Weighted Avg Shares (Diluted)38.73M58.74M79.66M110.46M160.98M

Cogent Biosciences, Inc.

NASDAQ:COGT

Intrinsic Alpha fair value

Locked

Current Price

$27.81

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.